PEG-MGF
PEGylated Mechano Growth Factor
PEG-MGF (PEGylated Mechano Growth Factor) is a modified version of the MGF splice variant of IGF-1 with polyethylene glycol chains attached to extend its biological half-life from minutes to several hours. This PEGylation converts MGF from a locally-acting autocrine factor into a systemically bioavailable peptide capable of reaching muscle tissue through the circulation. It is a research compound studied for enhanced muscle repair, recovery, and growth signaling with more practical dosing compared to unmodified MGF.
Mécanisme d'action
PEGylated version of mechano growth factor with polyethylene glycol chains attached to extend half-life. Preserves satellite cell activation and muscle repair properties of MGF while allowing systemic rather than purely local administration.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols use 200-400mcg 2-3 times per week via intramuscular injection into target muscle groups. Can be rotated across muscle groups. Cycles of 4-8 weeks.
Notes de recherche
Clinical Research Status
PEG-MGF has not entered formal clinical trials and remains a research-grade compound without regulatory status. Its development represents a pharmacokinetic optimization of the naturally-occurring MGF splice variant to address the impractically short half-life of the native peptide. Academic interest focuses on whether systemic delivery of PEGylated MGF can replicate the local satellite cell activation observed with natural MGF expression after exercise.
Key Published Findings
Animal studies suggest PEGylated MGF administered systemically can reach muscle tissue and promote satellite cell activation, though at lower local concentrations than achieved through direct intramuscular injection of native MGF. The PEGylation extends circulating half-life from approximately 5-7 minutes to several hours, allowing subcutaneous administration with meaningful systemic exposure. Research indicates the PEG moiety does not significantly impair receptor binding of the E-domain peptide.
Safety Profile
No human safety data exists for PEG-MGF, and risk assessment relies entirely on extrapolation from in vitro and animal studies. PEGylated compounds carry general risks of PEG-associated immune responses (anti-PEG antibodies) with repeated dosing, potentially reducing efficacy over time. The systemic nature of PEG-MGF raises broader safety considerations than local MGF, as satellite cell activation in non-target tissues (including cardiac muscle) could potentially occur.
Comparison to Related Compounds
Compared to unmodified MGF, PEG-MGF offers practical subcutaneous dosing but loses the tissue-specific local action that characterizes natural MGF biology. Unlike IGF-1 LR3 which activates the full IGF-1 receptor signaling cascade, PEG-MGF theoretically targets the earlier satellite cell activation phase rather than direct protein synthesis stimulation. The PEGylation approach mirrors pharmaceutical strategies used for other peptides (PEG-filgrastim, PEG-interferon) to reduce dosing frequency.
Community Observations
Protocols typically use PEG-MGF at 200-400 mcg administered subcutaneously on training days, based on empirical use rather than pharmacokinetic optimization. Some researchers question whether the PEGylated form adequately replicates the natural autocrine signaling pattern or whether systemic delivery fundamentally changes the biological response. The compound is often used in combination with IGF-1 LR3, with PEG-MGF theorized to expand satellite cell populations that IGF-1 LR3 then drives toward differentiation and hypertrophy.
Moitié de vie
~Several days
Réconstitution
Bacteriostatic water (BAC)
Conservation
Lyophilisé
Refrigerate 2-8C up to 18 months.
Réconstitué
Refrigerate 2-8C. Use within 14 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que PEG-MGF ?
PEG-MGF (PEGylated Mechano Growth Factor) is a modified version of the MGF splice variant of IGF-1 with polyethylene glycol chains attached to extend its biological half-life from minutes to several hours. This PEGylation converts MGF from a locally-acting autocrine factor into a systemically bioavailable peptide capable of reaching muscle tissue through the circulation. It is a research compound studied for enhanced muscle repair, recovery, and growth signaling with more practical dosing compared to unmodified MGF.
Comment agit PEG-MGF ?
PEGylated version of mechano growth factor with polyethylene glycol chains attached to extend half-life. Preserves satellite cell activation and muscle repair properties of MGF while allowing systemic rather than purely local administration.
Quel est le statut réglementaire de PEG-MGF aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de PEG-MGF ?
~Several days
Sous quels autres noms PEG-MGF est-il connu ?
PEGylated Mechano Growth Factor
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète